Evogene Partners with ELEO to Develop Oral PCSK9 Inhibitors for $23B Cardiovascular Market
EVGN sits 42% above its 52-week low of $0.37 on light trading volume (0.1× avg).
Summary
Evogene and South Korea's ELEO are teaming up to create next-generation oral small-molecule PCSK9 inhibitors for hyperlipidemia and cardiovascular disease. Evogene will use its ChemPass AI platform to design candidates, while ELEO provides biological validation and screening. The global PCSK9 inhibitor market is projected to reach over $23 billion by 2035, offering a substantial commercial opportunity. This collaboration adds a new pipeline program to Evogene's portfolio, which has been under pressure from an activist proxy fight and ongoing ATM dilution. The deal could attract future licensing or partnership interest from large pharma, but no financial terms were disclosed.
At the time of this announcement, EVGN was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $0.37 to $1.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.